For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1
The best therapy is the one patients actually take
Be confident your patients have received their dose with HCP-administered LEQVIO® — the only twice-yearly* LDL-C lowering therapy.
Are your patients ready to start LEQVIO? Find coverage in your area and fill out the Patient Start form to begin.
*After 2 initial doses and taken with statin therapy.
†An event is defined as acute coronary syndrome (unstable angina, STEMl, or NSTEMI). Patients were screened within 5 weeks from their coronary event.2
HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; PCSK9, proprotein convertase subtilisin/kexin type 9.
HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; PCSK9, proprotein convertase subtilisin/kexin type 9.